ReviewSteroids2018
Glucocorticoid receptor signaling in the eye.
Review in Steroids, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 62 citations in OpenAlex.
- Network Analysis of Convergent and Specific Molecular Pathways of Nutraceuticals with Antioxidant and Neuroprotective Potential in Glaucoma.Antioxidants (Basel, Switzerland) · 2026Article
- Retrospective analysis of clinical efficacy and safety of fluorometholone combined with azelastine eye drops for seasonal allergic conjunctivitis.Frontiers in medicine · 2026Article
- Differential MicroRNA Expression in the Anterior Lens Capsule of Patients with Glucocorticoid-Induced Cataracts: A Preliminary Study.Journal of clinical medicine · 2025Article
- Review
- Glucocorticoid-Dependent Retinal Degeneration and Vision Impairment in Mice Susceptible to Prenatal Stress-Induced Behavioral Abnormalities.Cellular and molecular neurobiology · 2024Article
- Glucocorticoid Receptor Signaling Is Critical for Mouse Corneal Development, Inhibition of Inflammatory Response, and Neovascularization of the Cornea.The American journal of pathology · 2024Article
- A bibliometric and visualized analysis of the pathogenesis of cataracts from 1999 to 2023.Heliyon · 2024Article
- The glucocorticoid receptor as a master regulator of the Müller cell response to diabetic conditions in mice.Journal of neuroinflammation · 2024Article
- Exosomes and their miRNA/protein profile in keratoconus-derived corneal stromal cells.Experimental eye research · 2023Article
- Next-generation nanomaterials: advancing ocular anti-inflammatory drug therapy.Journal of nanobiotechnology · 2023Review
- Association analysis of BclI with benign lymphoepithelial lesions of the lacrimal gland and glucocorticoids resistance.International journal of ophthalmology · 2023Article
- Differential distribution of steroid hormone signaling networks in the human choroid-retinal pigment epithelial complex.BMC ophthalmology · 2022Article
- Article
- Anterior pituitary, sex hormones, and keratoconus: Beyond traditional targets.Progress in retinal and eye research · 2022Article
- Regulation of herpes simplex virus type 1 latency-reactivation cycle and ocular disease by cellular signaling pathways.Experimental eye research · 2022Article
- Topical Anti-Inflammatory Agents for Non-Infectious Uveitis: Current Treatment and Perspectives.Journal of inflammation research · 2022Review
- Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.Drug delivery and translational research · 2021Review
- Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?Orphanet journal of rare diseases · 2021Review
- Thermo-Responsive PLGA-PEG-PLGA Hydrogels as Novel Injectable Platforms for Neuroprotective Combined Therapies in the Treatment of Retinal Degenerative Diseases.Pharmaceutics · 2021Article
- Dendrimer-Triamcinolone Acetonide Reduces Neuroinflammation, Pathological Angiogenesis, and Neuroretinal Dysfunction in Ischemic Retinopathy.Advanced therapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Glucocorticoids (GCs) are essential steroid hormones that regulate numerous metabolic and homeostatic functions in almost all physiological systems. Synthetic glucocorticoids are among the most commonly prescribed drugs for the treatment of various conditions including autoimmune, allergic and inflammatory diseases. Glucocorticoids are mainly used for their potent anti-inflammatory and immunosuppressive activities mediated through signal transduction by their nuclear receptor, the glucocorticoid receptor (GR). Emerging evidence showing that diverse physiological and therapeutic actions of glucocorticoids are tissue-, cell-, and sex-specific, suggests more complex actions of glucocorticoids than previously anticipated. While several synthetic glucocorticoids are widely used in the ophthalmology clinic for the treatment of several ocular diseases, little is yet known about the mechanism of glucocorticoid signaling in different layers of the eye. GR has been shown to be expressed in different cell types of the eye such as cornea, lens, and retina, suggesting an important role of GR signaling in the physiology of these ocular tissues. In this review, we provide an update on the recent findings from in vitro and in vivo studies reported in the last 5 years that aim at understanding the role of GR signaling specifically in the eye. Advances in studying the physiological effects of glucocorticoids in the eye are vital for the elaboration of optimized and targeted GC therapies with potent anti-inflammatory potential while minimizing adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.